Urs Jaisli - Roche Holding Insider

RHHVF -- USA Stock  

USD 246.51  1.51  0.62%

  Executive
We currently do not have informatin regarding Urs Jaisli. This executive tanure with Roche Holding AG is not currenlty determined.
Age: 61        
41 61 688 11 11  http://www.roche.com

Management Efficiency

The company has return on total asset (ROA) of 14.37 % which means that it generated profit of $14.37 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 31.85 % meaning that it generated $31.85 on every $100 dollars invested by stockholders.
The company has accumulated 19.15 B in total debt with debt to equity ratio (D/E) of 65.4 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Roche Holding AG has Current Ratio of 1.39 which is within standard range for the sector.

Similar Executives

Found 11 records

EXECUTIVE Since

Mingguang LiCHINA LIFE INSURANCE LTD
2017
Joseph LacsonMetro Pacific Investments Corpo
2016
Yong ZhengCHINA LIFE INSURANCE LTD
2013
Cheryll SerenoMegaworld Corporation
2018
Zhong ZhanCHINA LIFE INSURANCE LTD
1968
Rolando SiatelaMegaworld Corporation
N/A
Qi RuanCHINA LIFE INSURANCE LTD
2016
Jiade LiuCHINA LIFE INSURANCE LTD
2015
Johann QuiazonMegaworld Corporation
2017
Cristina GilFernandezMetro Pacific Investments Corpo
2013
Anna LlovidoMegaworld Corporation
2014

Entity Summary

Roche Holding AG diagnostics and pharmaceuticals businesses in Switzerland, Germany, and rest of Europe. The company was founded in 1896 and is headquartered in Basel, Switzerland. Roche Holding operates under Drug Manufacturers - Major classification in USA and traded on OTC Market. It employs 93734 people.Roche Holding AG (RHHVF) is traded on OTC Market in USA. It is located in Konzern Hauptsitz and employs 93,734 people.

Roche Holding AG Leadership Team

Osamu Nagayama, Member of the Enlarged Corporate Executive Committee and Presidentident and CEO of Chugai
Michael Varney, Member of the Enlarged Corporate Executive Committee, Head Genetech Research and Early Development
Silvia Ayyoubi, Head of Group HR
Sophie KornowskiBonnet, Member of the Enlarged Corporate Executive Committee, Head of Roche Partnering
Beatrice Mauro, Non-Executive Director
Cristina Wilbur, Member of the Executive Committee, Head Group Human Resources
Roland Diggelmann, Member of the Corporate Executive Committee, COO of the Division Roche Diagnostics
Gottlieb Keller, General Counsel and Corporate Secretary
Urs Jaisli, Chief Compliance Officer
Daniel ODay, COO of Pharmaceuticals division
DeAnne Julius, Non-Executive Director
Karl Mahler, Head of Investor Relations
Andre Hoffmann, Non-Executive Vice Chairman of the Board
John Reed, Member of the Enlarged Corporate Executive Committee, Head of Roche Pharma Research & Early Development
Claudia Dyckerhoff, Non-Executive Director
Fritz Gerber, Honorary Chairman of the Board
Stephan Feldhaus, Member of the Enlarged Corporate Executive Committee, Head Group Communications
Julie Brown, Non-Executive Director
Richard Lifton, Non-Executive Director
Paul Bulcke, Non-Executive Director
Christoph Franz, Non-Executive Director
PerOlof Attinger, Secretary to the Corporate Executive Committee, Head CEO Office
Pius Baschera, Non-Executive Director
Peter Voser, Non-Executive Director
Bernard Poussot, Non-Executive Director
John Bell, Non-Executive Director
Andreas Oeri, Non-Executive Director
Alan Hippe, CFO and IT Officer
F Hoffmann, IR Contact Officer
Severin Schwan, CEO and Director
Anita Hauser, Non-Executive Director

Stock Performance Indicators

Did you try this?

Run Portfolio Manager Now

   

Portfolio Manager

State of the art Portfolio Manager to monitor and improve performance of your invested capital
All  Next Launch Portfolio Manager
Currently Active Assets on Macroaxis
CRM   
Purchased a lot of shares of
2 days ago
Traded for 156.0
CRM   
Purchased a lot of shares of
2 days ago
Traded for 156.0
F   
Purchased over 300 shares of
2 days ago
Traded for 9.81
C   
Purchased over 40 shares of
2 days ago
Traded for 74.735
GM   
Purchased over 70 shares of
2 days ago
Traded for 36.08
Additionally take a look at Your Equity Center. Please also try Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Search macroaxis.com